
Global R&D Pipeline
My Favorite
Hot Targets:
ADCYAP1R1
Back
Total number of drugs
7
Phase II and later clinical stages
14.3%
Involving companies
8
Main therapeutic areas
Nervous System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-CGRPR/PAC1R bispecific antibody(Amgen) | Anti-CGRPR/PAC1R bispecific antibody(Amgen) | Bispecific antibody | Nervous System Diseases | Pituitary adenylate cyclase-activating polypeptide type I receptor antagonists Calcitonin gene-related peptide type 1 receptor antagonists | Amgen, Inc. | Amgen, Inc. | Preclinical | Anti-CGRPR/PAC1R bispecific antibody(Amgen) | detail > | ||||||||||||
| BAY 2686013 | BAY 2686013 | Small molecule drug | Nervous System Diseases | Pituitary adenylate cyclase-activating polypeptide type I receptor antagonists | Bayer AG | Bayer AG | Preclinical | BAY 2686013 | detail > | ||||||||||||
| MT-001 (Mentari) | MT-001 (Mentari) | Monoclonal antibody | Nervous System Diseases | Pituitary adenylate cyclase-activating polypeptide type I receptor antagonists | Paragon Therapeutics, Inc. | Mentari Therapeutics, Inc. | Preclinical | MT-001 (Mentari) | detail > | ||||||||||||
| MT-002 (Mentari) | MT-002 (Mentari) | Bispecific antibody | Nervous System Diseases | Pituitary adenylate cyclase-activating polypeptide type I receptor antagonists Calcitonin gene-related peptide antagonists | Paragon Therapeutics, Inc. | Mentari Therapeutics, Inc. | Preclinical | MT-002 (Mentari) | detail > | ||||||||||||
| SPAM1 | SPAM1 | Small molecule drug | Pituitary adenylate cyclase-activating polypeptide type I receptor modulators | Jinan University | Jinan University | Preclinical | Preclinical | SPAM1 | detail > | ||||||||||||
| MAXCAPs | MAXCAPs | Fusion protein | Digestive System Disorders | Pituitary adenylate cyclase-activating polypeptide type I receptor agonists | Bausch Health Cos., Inc.University of California, Los AngelesSalix Pharmaceuticals, Inc. | Preclinical | MAXCAPs | detail > | |||||||||||||
| Zelminemab | Zelminemab | Monoclonal antibody | Nervous System Diseases | Pituitary adenylate cyclase-activating polypeptide type I receptor antagonists | Amgen, Inc. | Phase 2 | Zelminemab | detail > |
Total 7 data
1


